0

Biosimilars Market by Product Type, Application, and Geography - Forecast and Analysis 2023-2027

  • Published: Nov 2022
  • Pages: 172
  • SKU: IRTNTR70710
Technavio

Enjoy complimentary customisation on priority with our Enterprise License!

Safe and Secure SSL Encrypted

info
close
  • Single:

    One user only.
    Quick & easy download option

  • Enterprise:

    Unlimited user access (Within your organization)
    Complimentary Customization Included

2500 USD

The biosimilars market is estimated to grow at a CAGR of 23% between 2022 and 2027. The size of the market is forecast to increase by USD 42,227.12 million. The growth of the market depends on serval factors, including the price advantage of biosimilars over biologics, the patent expiry of major biologics, and government initiatives to increase the use of biosimilar medicines.

This report extensively covers market segmentation by product type (monoclonal antibodies, insulin, human growth hormone, and others), application (oncology and hematology, endocrinology, immunology, and nephrology), and geography (Europe, North America, Asia, and Rest of World (ROW)). It also includes an in-depth analysis of drivers, trends, and challenges. Furthermore, the report includes historic market data from 2017 to 2021.

 What will the Size of the Biosimilars Market be During the Forecast Period?

Biosimilars Market Size

To learn more about this report, Download Report Sample

Parent Market Analysis

The reports categorize the global biosimilars market as a part of the global pharmaceuticals market. The parent global pharmaceuticals market covers products and companies engaged in the R&D or production of generic drugs, non-generic drugs, and veterinary drugs. Growth in the global pharmaceuticals market will be driven by improving access to better healthcare in emerging economies. Our research report has extensively covered external factors influencing the parent market growth during the forecast period.

Biosimilars Market: Key Drivers, Trends, Challenges, and Customer Landscape

The price advantage of biosimilars over biologics is notably driving the market growth, although factors such as market access barriers for biosimilars may impede the market growth. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.

Key Biosimilars Market Driver 

The price advantage of biosimilars over biologics is notably driving the market growth. The high cost of biologics reduces patients' access to these products and increases total healthcare costs. A biosimilar is a copy of the biologic, which has been already authorized for use and is priced 20%-25% less than the originator biologic. The reason for the decrease in the cost of a biosimilar could be attributed to the lower number of clinical trials for a biosimilar when compared with the original biologic. Another reason for the low cost of a biosimilar is that it does not have any associated marketing costs or post-marketing R&D costs.

The advancements in genetic engineering and a decrease in the scale-up costs for recombinant proteins have also made it feasible to manufacture biosimilars at low costs. The cost of biosimilars could be further reduced if the cost associated with the approval of biosimilars can be reduced. The EMA and the US FDA guidelines modifications could ensure unnecessary repetition of clinical trials. The Biologics Price Competition and Innovation Act is intended to encourage biosimilars and drive down the cost even further, which in turn would drive the market growth during the forecast period.

Key Biosimilars Market Trend

Biosimilar's patent dance is the key trend driving the biosimilar market growth. After the submission of the application, to remove and resolve any patent-related disputes, there is a legal procedure known as patent dance. Enacted in March 2010 by the Biologics Price Competition and Innovation Act of 2009 (BPCIA), the patent dance aims to resolve any patent disputes systematically. Since the biosimilars are identical replicas to their bio-originator products, there are chances of having patent litigation between the bio-originator sponsor and the biosimilar applicant at the time of getting approvals. Patent dance is a statutory framework in which the biosimilar applicant must provide the bio-originator product sponsor all the confidential information related to manufacturing and biosimilar application. The act further necessitates that a notice of the biosimilar product should be given to the reference product sponsor not later than 180 days before the first date of marketing by the biosimilar applicant. The patent dance focuses on avoiding disputes at the time of product launch so that neither the applicant nor the bio-originator sponsor faces any problems.

Key Biosimilars Market Challenge

Market access barriers for biosimilars is the major challenge impeding the market growth. To compete with biologics and to get entry into the market, biosimilars are facing several challenges. The first challenge is the sophisticated manufacturing process associated with biosimilars. The uniformity of the product needs to be maintained, and it is known that even between two batches of the same product, variations are likely to occur. The manufacturing of biosimilar or biologics involves a complex manufacturing process, which is the biggest challenge for a new company to overcome.

The manufacturing complexities are not a hurdle to the companies that have experience in making biologics and will continue to dominate the market. Another challenge is that there are legal issues associated with the approval process for biologics. A single biosimilar takes a lot of time to get approval through the clinical trial process is reduced. The substitution and interchangeability of the biosimilars are not feasible as that of the generic drugs. In addition, safety, pricing, and physician and patient acceptance have also become potential barriers to biosimilar entry.

Key Biosimilars Market Customer Landscape

The report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.

Biosimilars Market Share by Geography

Global Biosimilars Market Customer Landscape

 

Who are the Major Biosimilars Market Vendors?                                     

Vendors are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.

Fresenius SE & Co. KGaA - The company offers biosimilars such as Adalimumab, Tocilizumab, and Pegfilgrastim as its key offerings under its medical care segment. This segment also provides dialysis products such as hemodialysis machines, dialyzers and related disposable products. Additionally, through its generic drug segment, it provides products such as intravenous generic drugs, infusion therapies, and clinical nutrition products. It also provides devices for administering these products.

The report also includes detailed analyses of the competitive landscape of the market and information about 15 market vendors, including:

  • AbbVie Inc.
  • Amgen Inc.
  • Biocon Ltd.
  • Biogen Inc.
  • Boehringer Ingelheim International GmbH
  • Celltrion Healthcare Co. Ltd.
  • Dr Reddys Laboratories Ltd.
  • F. Hoffmann La Roche Ltd.
  • Gedeon Richter Plc
  • Halozyme Therapeutics Inc
  • Intas Pharmaceuticals Ltd.
  • Mabion S.A.
  • Novartis AG
  • Pfizer Inc.
  • Samsung Biologics Co. Ltd.

Qualitative and quantitative analysis of vendors has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize vendors as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize vendors as dominant, leading, strong, tentative, and weak.

What is the Fastest-Growing Segment in the Biosimilars Market?

The market share growth by the monoclonal antibodies segment (mAbs) will be significant during the forecast period. Biosimilar mAbs represent an opportunity to increase access to mAbs the patients due to their lower costs. These are key drugs indicated for the treatment of various cancers and autoimmune disorders such as rheumatoid arthritis. The rapid development of biosimilars for complex mAbs is expected to accelerate market growth during the forecast period. The primary factors for this growth include the patent expiry of blockbuster mAbs, coupled with the approval of biosimilar mAbs, and the increasing prevalence of chronic diseases. 

Biosimilars Market Size

Get a glance at the market contribution of various segments  Request a PDF Sample

The monoclonal antibodies segment shows a gradual increase in the market share of USD 2,339 million in 2017 and continue to grow by 2021. Biosimilar monoclonal antibodies (mAbs) are large, complex proteins used by the immune system to identify and neutralize foreign bodies such as bacteria and viruses. They are used for the treatment of cancers such as breast cancer and non-cancer diseases such as rheumatoid arthritis. They are also highly similar to the originator mAbs and cost-effective. Several vendors are developing biosimilar mAbs as they are cost-effective treatments. For instance, the European Union and the US FDA recently approved five trastuzumab biosimilars. Such an increasing number of biosimilar mAbs gaining approval will drive the market growth during the forecast period.

Which are the Key Regions for the Biosimilars Market?

Biosimilars Market Share by Geography

For more insights on the market share of various regions Request PDF Sample now!

Europe is projected to contribute 46% by 2023. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

Europe approved sixteen biosimilars of seven different biologic products in 2020, thus expanding the biosimilar market into new therapeutic areas and newer classes of biologics for which no biosimilars have been previously approved in the EU. In many EU countries, including Germany and Sweden, biosimilar substitution is allowed for specific groups of biosimilars manufactured by the same pharmaceutical company. France is among the first EU country to establish a law for biosimilar substitution in treatment-naive patients or to continue a treatment already initiated with the same biosimilar. 

In 2020, the outbreak of COVID-19 impeded the demand for biosimilars due to the decreased focus on cancer. However, key vendors are working on various collaborations and M&As to cope-up with the COVID-19 situation. Moreover, initiatives from governments to overcome the pandemic are also expected to enhance the growth of the market during the forecast period. For instance, on April 17, 2020, the NIH announced the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) public-private partnership to develop a coordinated research strategy for prioritizing and speeding the development of the most promising treatments and vaccines.

Segment Overview

The report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2017 to 2027. The market has been segmented by product type, application, and region. 

  • Product Type Outlook ( USD Million, 2017 - 2027)
    • Monoclonal antibodies
    • Insulin
    • Human growth hormone
    • Others
  • Application Outlook ( USD Million, 2017 - 2027)
    • Oncology and hematology
    • Endocrinology
    • Immunology
    • Nephrology
  • Region Outlook ( USD Million, 2017 - 2027)
    • Europe
      • U.K.
      • Germany
      • France
      • Rest of Europe
    • North America
      • The U.S.
      • Canada
    • Asia
      • China
      • India
      • Singapore
    • Rest of World (ROW)
      • Brazil
      • Argentina
      • Rest of the Middle East & Africa

Biosimilars Market Scope

Report Coverage

Details

Page number

172

Base year

2022

Historic period

2017-2021

Forecast period

2023-2027

Growth momentum & CAGR

Accelerate at a CAGR of 23%

Market growth 2023-2027

USD 42,227.12 million

Market structure

Fragmented

YoY growth (%)

22.9

Regional analysis

Europe, North America, Asia, and Rest of World (ROW)

Performing market contribution

Europe at 46%

Key countries

US, Germany, UK, China, and Republic of Korea

Competitive landscape

Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks

Key companies profiled

AbbVie Inc., Amgen Inc., Biocon Ltd., Biogen Inc., Boehringer Ingelheim International GmbH, Celltrion Healthcare Co. Ltd., Dr Reddys Laboratories Ltd., F. Hoffmann La Roche Ltd., Fresenius SE and Co. KGaA, Gedeon Richter Plc, Halozyme Therapeutics Inc, Intas Pharmaceuticals Ltd., Mabion S.A., Novartis AG, Pfizer Inc., Samsung Biologics Co. Ltd., Sanofi SA, Teva Pharmaceutical Industries Ltd., and Viatris Inc.

Market dynamics

Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and market condition analysis for the forecast period.

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Request PDF sample

What are the Key Data Covered in this Biosimilars Market Report?

  • CAGR of the market during the forecast period.
  • Detailed information on factors that will drive the growth of the market between 2023 and 2027
  • Precise estimation of the biosimilars market size and contribution of the market in focus to the parent market.
  • Accurate predictions about upcoming trends and changes in consumer behavior.
  • Growth of the market industry across Europe, North America, Asia, and Rest of World (ROW).
  • Thorough analysis of the market’s competitive landscape and detailed information about vendors.
  • Comprehensive analysis of factors that will challenge the growth of biosimilar market vendors.

We can help! Our analysts can customize this report to meet your requirements. Get in touch

1 Executive Summary

  • 1.1 Market overview
    • Exhibit 01: Executive Summary – Chart on Market Overview
    • Exhibit 02: Executive Summary – Data Table on Market Overview
    • Exhibit 03: Executive Summary – Chart on Global Market Characteristics
    • Exhibit 04: Executive Summary – Chart on Market by Geography
    • Exhibit 05: Executive Summary – Chart on Market Segmentation by Product Type
    • Exhibit 06: Executive Summary – Chart on Market Segmentation by Application
    • Exhibit 07: Executive Summary – Chart on Incremental Growth
    • Exhibit 08: Executive Summary – Data Table on Incremental Growth
    • Exhibit 09: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

  • 2.1 Market ecosystem
    • Exhibit 10: Parent market
    • Exhibit 11: Market Characteristics

3 Market Sizing

  • 3.1 Market definition
    • Exhibit 12: Offerings of vendors included in the market definition
  • 3.2 Market segment analysis
    • Exhibit 13: Market segments
  • 3.3 Market size 2022
    • 3.4 Market outlook: Forecast for 2022-2027
      • Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million)
      • Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
      • Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
      • Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)

    4 Historic Market Size

    • 4.1 Global biosimilars market 2017 - 2021
      • Exhibit 18: Historic Market Size – Data Table on Global biosimilars market 2017 - 2021 ($ million)
    • 4.2 Product Segment Analysis 2017 - 2021
      • Exhibit 19: Historic Market Size – Product Segment 2017 - 2021 ($ million)
    • 4.3 Application Segment Analysis 2017 - 2021
      • Exhibit 20: Historic Market Size – Application Segment 2017 - 2021 ($ million)
    • 4.4 Geography Segment Analysis 2017 - 2021
      • Exhibit 21: Historic Market Size – Geography Segment 2017 - 2021 ($ million)
    • 4.5 Country Segment Analysis 2017 - 2021
      • Exhibit 22: Historic Market Size – Country Segment 2017 - 2021 ($ million)

    5 Five Forces Analysis

    • 5.1 Five forces summary
      • Exhibit 23: Five forces analysis - Comparison between 2022 and 2027
    • 5.2 Bargaining power of buyers
      • Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027
    • 5.3 Bargaining power of suppliers
      • Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027
    • 5.4 Threat of new entrants
      • Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027
    • 5.5 Threat of substitutes
      • Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027
    • 5.6 Threat of rivalry
      • Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027
    • 5.7 Market condition
      • Exhibit 29: Chart on Market condition - Five forces 2022 and 2027

    6 Market Segmentation by Product Type

    • 6.1 Market segments
      • Exhibit 30: Chart on Product Type - Market share 2022-2027 (%)
      • Exhibit 31: Data Table on Product Type - Market share 2022-2027 (%)
    • 6.2 Comparison by Product Type
      • Exhibit 32: Chart on Comparison by Product Type
      • Exhibit 33: Data Table on Comparison by Product Type
    • 6.3 Monoclonal antibodies - Market size and forecast 2022-2027
      • Exhibit 34: Chart on Monoclonal antibodies - Market size and forecast 2022-2027 ($ million)
      • Exhibit 35: Data Table on Monoclonal antibodies - Market size and forecast 2022-2027 ($ million)
      • Exhibit 36: Chart on Monoclonal antibodies - Year-over-year growth 2022-2027 (%)
      • Exhibit 37: Data Table on Monoclonal antibodies - Year-over-year growth 2022-2027 (%)
    • 6.4 Insulin - Market size and forecast 2022-2027
      • Exhibit 38: Chart on Insulin - Market size and forecast 2022-2027 ($ million)
      • Exhibit 39: Data Table on Insulin - Market size and forecast 2022-2027 ($ million)
      • Exhibit 40: Chart on Insulin - Year-over-year growth 2022-2027 (%)
      • Exhibit 41: Data Table on Insulin - Year-over-year growth 2022-2027 (%)
    • 6.5 Human growth hormone - Market size and forecast 2022-2027
      • Exhibit 42: Chart on Human growth hormone - Market size and forecast 2022-2027 ($ million)
      • Exhibit 43: Data Table on Human growth hormone - Market size and forecast 2022-2027 ($ million)
      • Exhibit 44: Chart on Human growth hormone - Year-over-year growth 2022-2027 (%)
      • Exhibit 45: Data Table on Human growth hormone - Year-over-year growth 2022-2027 (%)
    • 6.6 Others - Market size and forecast 2022-2027
      • Exhibit 46: Chart on Others - Market size and forecast 2022-2027 ($ million)
      • Exhibit 47: Data Table on Others - Market size and forecast 2022-2027 ($ million)
      • Exhibit 48: Chart on Others - Year-over-year growth 2022-2027 (%)
      • Exhibit 49: Data Table on Others - Year-over-year growth 2022-2027 (%)
    • 6.7 Market opportunity by Product Type
      • Exhibit 50: Market opportunity by Product Type ($ million)

    7 Market Segmentation by Application

    • 7.1 Market segments
      • Exhibit 51: Chart on Application - Market share 2022-2027 (%)
      • Exhibit 52: Data Table on Application - Market share 2022-2027 (%)
    • 7.2 Comparison by Application
      • Exhibit 53: Chart on Comparison by Application
      • Exhibit 54: Data Table on Comparison by Application
    • 7.3 Oncology and hematology - Market size and forecast 2022-2027
      • Exhibit 55: Chart on Oncology and hematology - Market size and forecast 2022-2027 ($ million)
      • Exhibit 56: Data Table on Oncology and hematology - Market size and forecast 2022-2027 ($ million)
      • Exhibit 57: Chart on Oncology and hematology - Year-over-year growth 2022-2027 (%)
      • Exhibit 58: Data Table on Oncology and hematology - Year-over-year growth 2022-2027 (%)
    • 7.4 Endocrinology - Market size and forecast 2022-2027
      • Exhibit 59: Chart on Endocrinology - Market size and forecast 2022-2027 ($ million)
      • Exhibit 60: Data Table on Endocrinology - Market size and forecast 2022-2027 ($ million)
      • Exhibit 61: Chart on Endocrinology - Year-over-year growth 2022-2027 (%)
      • Exhibit 62: Data Table on Endocrinology - Year-over-year growth 2022-2027 (%)
    • 7.5 Immunology - Market size and forecast 2022-2027
      • Exhibit 63: Chart on Immunology - Market size and forecast 2022-2027 ($ million)
      • Exhibit 64: Data Table on Immunology - Market size and forecast 2022-2027 ($ million)
      • Exhibit 65: Chart on Immunology - Year-over-year growth 2022-2027 (%)
      • Exhibit 66: Data Table on Immunology - Year-over-year growth 2022-2027 (%)
    • 7.6 Nephrology - Market size and forecast 2022-2027
      • Exhibit 67: Chart on Nephrology - Market size and forecast 2022-2027 ($ million)
      • Exhibit 68: Data Table on Nephrology - Market size and forecast 2022-2027 ($ million)
      • Exhibit 69: Chart on Nephrology - Year-over-year growth 2022-2027 (%)
      • Exhibit 70: Data Table on Nephrology - Year-over-year growth 2022-2027 (%)
    • 7.7 Market opportunity by Application
      • Exhibit 71: Market opportunity by Application ($ million)

    8 Customer Landscape

    • 8.1 Customer landscape overview
      • Exhibit 72: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

    9 Geographic Landscape

    • 9.1 Geographic segmentation
      • Exhibit 73: Chart on Market share by geography 2022-2027 (%)
      • Exhibit 74: Data Table on Market share by geography 2022-2027 (%)
    • 9.2 Geographic comparison
      • Exhibit 75: Chart on Geographic comparison
      • Exhibit 76: Data Table on Geographic comparison
    • 9.3 Europe - Market size and forecast 2022-2027
      • Exhibit 77: Chart on Europe - Market size and forecast 2022-2027 ($ million)
      • Exhibit 78: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
      • Exhibit 79: Chart on Europe - Year-over-year growth 2022-2027 (%)
      • Exhibit 80: Data Table on Europe - Year-over-year growth 2022-2027 (%)
    • 9.4 North America - Market size and forecast 2022-2027
      • Exhibit 81: Chart on North America - Market size and forecast 2022-2027 ($ million)
      • Exhibit 82: Data Table on North America - Market size and forecast 2022-2027 ($ million)
      • Exhibit 83: Chart on North America - Year-over-year growth 2022-2027 (%)
      • Exhibit 84: Data Table on North America - Year-over-year growth 2022-2027 (%)
    • 9.5 Asia - Market size and forecast 2022-2027
      • Exhibit 85: Chart on Asia - Market size and forecast 2022-2027 ($ million)
      • Exhibit 86: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
      • Exhibit 87: Chart on Asia - Year-over-year growth 2022-2027 (%)
      • Exhibit 88: Data Table on Asia - Year-over-year growth 2022-2027 (%)
    • 9.6 Rest of World (ROW) - Market size and forecast 2022-2027
      • Exhibit 89: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
      • Exhibit 90: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
      • Exhibit 91: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
      • Exhibit 92: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
    • 9.7 Germany - Market size and forecast 2022-2027
      • Exhibit 93: Chart on Germany - Market size and forecast 2022-2027 ($ million)
      • Exhibit 94: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
      • Exhibit 95: Chart on Germany - Year-over-year growth 2022-2027 (%)
      • Exhibit 96: Data Table on Germany - Year-over-year growth 2022-2027 (%)
    • 9.8 US - Market size and forecast 2022-2027
      • Exhibit 97: Chart on US - Market size and forecast 2022-2027 ($ million)
      • Exhibit 98: Data Table on US - Market size and forecast 2022-2027 ($ million)
      • Exhibit 99: Chart on US - Year-over-year growth 2022-2027 (%)
      • Exhibit 100: Data Table on US - Year-over-year growth 2022-2027 (%)
    • 9.9 UK - Market size and forecast 2022-2027
      • Exhibit 101: Chart on UK - Market size and forecast 2022-2027 ($ million)
      • Exhibit 102: Data Table on UK - Market size and forecast 2022-2027 ($ million)
      • Exhibit 103: Chart on UK - Year-over-year growth 2022-2027 (%)
      • Exhibit 104: Data Table on UK - Year-over-year growth 2022-2027 (%)
    • 9.10 China - Market size and forecast 2022-2027
      • Exhibit 105: Chart on China - Market size and forecast 2022-2027 ($ million)
      • Exhibit 106: Data Table on China - Market size and forecast 2022-2027 ($ million)
      • Exhibit 107: Chart on China - Year-over-year growth 2022-2027 (%)
      • Exhibit 108: Data Table on China - Year-over-year growth 2022-2027 (%)
    • 9.11 Republic of Korea - Market size and forecast 2022-2027
      • Exhibit 109: Chart on Republic of Korea - Market size and forecast 2022-2027 ($ million)
      • Exhibit 110: Data Table on Republic of Korea - Market size and forecast 2022-2027 ($ million)
      • Exhibit 111: Chart on Republic of Korea - Year-over-year growth 2022-2027 (%)
      • Exhibit 112: Data Table on Republic of Korea - Year-over-year growth 2022-2027 (%)
    • 9.12 Market opportunity by geography
      • Exhibit 113: Market opportunity by geography ($ million)

    10 Drivers, Challenges, and Trends

    • 10.1 Market drivers
      • 10.2 Market challenges
        • 10.3 Impact of drivers and challenges
          • Exhibit 114: Impact of drivers and challenges in 2022 and 2027
        • 10.4 Market trends

          11 Vendor Landscape

          • 11.1 Overview
            • 11.2 Vendor landscape
              • Exhibit 115: Overview on Criticality of inputs and Factors of differentiation
            • 11.3 Landscape disruption
              • Exhibit 116: Overview on factors of disruption
            • 11.4 Industry risks
              • Exhibit 117: Impact of key risks on business

            12 Vendor Analysis

            • 12.1 Vendors covered
              • Exhibit 118: Vendors covered
            • 12.2 Market positioning of vendors
              • Exhibit 119: Matrix on vendor position and classification
            • 12.3 AbbVie Inc.
              • Exhibit 120: AbbVie Inc. - Overview
              • Exhibit 121: AbbVie Inc. - Product / Service
              • Exhibit 122: AbbVie Inc. - Key offerings
            • 12.4 Amgen Inc.
              • Exhibit 123: Amgen Inc. - Overview
              • Exhibit 124: Amgen Inc. - Product / Service
              • Exhibit 125: Amgen Inc. - Key offerings
            • 12.5 Biocon Ltd.
              • Exhibit 126: Biocon Ltd. - Overview
              • Exhibit 127: Biocon Ltd. - Business segments
              • Exhibit 128: Biocon Ltd. - Key offerings
              • Exhibit 129: Biocon Ltd. - Segment focus
            • 12.6 Biogen Inc.
              • Exhibit 130: Biogen Inc. - Overview
              • Exhibit 131: Biogen Inc. - Product / Service
              • Exhibit 132: Biogen Inc. - Key offerings
            • 12.7 Boehringer Ingelheim International GmbH
              • Exhibit 133: Boehringer Ingelheim International GmbH - Overview
              • Exhibit 134: Boehringer Ingelheim International GmbH - Business segments
              • Exhibit 135: Boehringer Ingelheim International GmbH - Key news
              • Exhibit 136: Boehringer Ingelheim International GmbH - Key offerings
              • Exhibit 137: Boehringer Ingelheim International GmbH - Segment focus
            • 12.8 Celltrion Healthcare Co. Ltd.
              • Exhibit 138: Celltrion Healthcare Co. Ltd. - Overview
              • Exhibit 139: Celltrion Healthcare Co. Ltd. - Product / Service
              • Exhibit 140: Celltrion Healthcare Co. Ltd. - Key offerings
            • 12.9 Dr Reddys Laboratories Ltd.
              • Exhibit 141: Dr Reddys Laboratories Ltd. - Overview
              • Exhibit 142: Dr Reddys Laboratories Ltd. - Business segments
              • Exhibit 143: Dr Reddys Laboratories Ltd. - Key offerings
              • Exhibit 144: Dr Reddys Laboratories Ltd. - Segment focus
            • 12.10 F. Hoffmann La Roche Ltd.
              • Exhibit 145: F. Hoffmann La Roche Ltd. - Overview
              • Exhibit 146: F. Hoffmann La Roche Ltd. - Business segments
              • Exhibit 147: F. Hoffmann La Roche Ltd. - Key news
              • Exhibit 148: F. Hoffmann La Roche Ltd. - Key offerings
              • Exhibit 149: F. Hoffmann La Roche Ltd. - Segment focus
            • 12.11 Fresenius SE and Co. KGaA
              • Exhibit 150: Fresenius SE and Co. KGaA - Overview
              • Exhibit 151: Fresenius SE and Co. KGaA - Business segments
              • Exhibit 152: Fresenius SE and Co. KGaA - Key news
              • Exhibit 153: Fresenius SE and Co. KGaA - Key offerings
              • Exhibit 154: Fresenius SE and Co. KGaA - Segment focus
            • 12.12 Gedeon Richter Plc
              • Exhibit 155: Gedeon Richter Plc - Overview
              • Exhibit 156: Gedeon Richter Plc - Business segments
              • Exhibit 157: Gedeon Richter Plc - Key news
              • Exhibit 158: Gedeon Richter Plc - Key offerings
              • Exhibit 159: Gedeon Richter Plc - Segment focus
            • 12.13 Halozyme Therapeutics Inc
              • Exhibit 160: Halozyme Therapeutics Inc - Overview
              • Exhibit 161: Halozyme Therapeutics Inc - Product / Service
              • Exhibit 162: Halozyme Therapeutics Inc - Key offerings
            • 12.14 Intas Pharmaceuticals Ltd.
              • Exhibit 163: Intas Pharmaceuticals Ltd. - Overview
              • Exhibit 164: Intas Pharmaceuticals Ltd. - Product / Service
              • Exhibit 165: Intas Pharmaceuticals Ltd. - Key offerings
            • 12.15 Mabion S.A.
              • Exhibit 166: Mabion S.A. - Overview
              • Exhibit 167: Mabion S.A. - Product / Service
              • Exhibit 168: Mabion S.A. - Key offerings
            • 12.16 Novartis AG
              • Exhibit 169: Novartis AG - Overview
              • Exhibit 170: Novartis AG - Business segments
              • Exhibit 171: Novartis AG - Key offerings
              • Exhibit 172: Novartis AG - Segment focus
            • 12.17 Viatris Inc.
              • Exhibit 173: Viatris Inc. - Overview
              • Exhibit 174: Viatris Inc. - Business segments
              • Exhibit 175: Viatris Inc. - Key offerings
              • Exhibit 176: Viatris Inc. - Segment focus

            13 Appendix

            • 13.1 Scope of the report
              • 13.2 Inclusions and exclusions checklist
                • Exhibit 177: Inclusions checklist
                • Exhibit 178: Exclusions checklist
              • 13.3 Currency conversion rates for US$
                • Exhibit 179: Currency conversion rates for US$
              • 13.4 Research methodology
                • Exhibit 180: Research methodology
                • Exhibit 181: Validation techniques employed for market sizing
                • Exhibit 182: Information sources
              • 13.5 List of abbreviations
                • Exhibit 183: List of abbreviations

              Research Framework

              Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

              TechnavioINFORMATION SOURCES

              Primary sources

              • Manufacturers and suppliers
              • Channel partners
              • Industry experts
              • Strategic decision makers

              Secondary sources

              • Industry journals and periodicals
              • Government data
              • Financial reports of key industry players
              • Historical data
              • Press releases
              Technavio

              TechnavioDATA ANALYSIS

              Data Synthesis

              • Collation of data
              • Estimation of key figures
              • Analysis of derived insights

              Data Validation

              • Triangulation with data models
              • Reference against proprietary databases
              • Corroboration with industry experts
              Technavio

              TechnavioREPORT WRITING

              Qualitative

              • Market drivers
              • Market challenges
              • Market trends
              • Five forces analysis

              Quantitative

              • Market size and forecast
              • Market segmentation
              • Geographical insights
              • Competitive landscape
              Interested in this report?
              Get your sample now!
              Biosimilars market growth will increase by $31.40 billion during 2020-2025.
              The biosimilars market is expected to grow at a CAGR of 24.77% during 2020-2025.
              Technavio has segmented the biosimilars market by application (Oncology and hematology, Immunology, Endocrinology, Nephrology, Oncology and hematology, Immunology, Endocrinology, and Nephrology).
              Amgen Inc., Biogen Inc., Boehringer Ingelheim International GmbH, Eli Lilly and Co., F. Hoffmann-La Roche Ltd., Fresenius Kabi AG, Merck and Co. Inc., Novartis AG, Pfizer Inc., Viatris Inc. are a few of the key vendors in the biosimilars market.
              Europe will register the highest growth rate of 37.88% among the other regions. Therefore, the biosimilars market in Europe is expected to garner significant business opportunities for the vendors during the forecast period.
              • Germany
              • China
              • US
              • UK
              • South Korea (Republic of Korea)
              The key factors driving the biosimilars market growth are:
              • Price advantage of biosimilars over biologics
              The biosimilars market vendors should focus on grabbing business opportunities from the segment as it accounted for the largest market share in the base year.
              • What are the key global market and the regional market share?
              • What are the revenue-generating key market segments?
              • What are the key factors driving and challenging this market’s growth?
              • Who are the key market vendors and their growth strategies?
              • What are the latest trends influencing the growth of this market?
              • What are the variables influencing the market growth in the primary regions?
              • What are the factors influencing the growth of the parent market?
              • Off-the-shelf research reports
              • Reports can be tailored to meet the customer's needs
              • Trusted by more than 100 fortune 500 organizations
              • Information about the market's key drivers, trends, and challenges
              • Parent market analysis
              • Every week, 50,000 people visit our subscription platform
              • Detailed vendors report with competitive landscape
              • Covid-19 impact and recovery analysis
              • Data on revenue-generating market segments
              • Details on the market shares of various regions
              • Five-force market analysis

              Certified ISO 9001 : 2015

              We are ISO recognized

              We are ISO 9001:2015 recognized that ensures quality services and product delivery to our clients.

              We are GDPR and CCPA compliant

              We are GDPR and CCPA compliant! Your transaction & personal information is protected from unauthorized use.

              Safe and Secure SSL Encrypted
              Technavio

              info
              close
              • Single:

                One user only.
                Quick & easy download option

              • Enterprise:

                Unlimited user access (Within your organization)
                Complimentary Customization Included

              2500 USD

              Technavio Get the report (PDF) sent to your email within minutes.

              Subscribe & Save

              Get lifetime access to our
              Technavio Insights

              Customized Report as per your Business Needs

              • Our analysts will work directly with you and understand your needs
              • Get data on specified regions or segments, competitor and Vendors
              • Data will be formatted and presented as per your requirements
              • We offer $1000 worth of FREE customization at the time of purchase

              Let us help you make report more suited to your requirements.

              • Get a competitive breakdown as per your niche industry
              • Customize the data with various metrics that meet your business prerequisite
              • Understand Revenue Sources, Customers and many more
              • Details on Market Share
              • These customizations are done in a short amount of time by our analysts and industry experts
              Technavio
              Enquire Before Buying
              17,000 reports available | Plans starting from just 5,000 USD | Get FREE trial>>